ÂÜÀòÂÒÂ×

Irene Gil Farina has extensive work experience in the field of research and development, particularly in the areas of cell and gene therapy. Their most recent position is as the Vice President of R&D at Noscendo GmbH, where they started in November 2022. Prior to this, they worked at ProtaGene as the Senior Director of Cell and Gene Therapy R&D from January 2022 to October 2022.

Irene previously held roles at GeneWerk, starting in December 2016 and working their way up to Head of Research and Development from March 2019 to October 2022. Before that, they served as a Scientific Consultant/R&D at GeneWerk from December 2016 to February 2019.

Before joining GeneWerk, Irene worked as a Postdoctoral Researcher at dkfz - German Cancer Research Center from October 2014 to December 2019. Their doctoral studies were conducted at the Centre for Applied Medical Research (CIMA) - Department of Gene Therapy and Hepatology, where they were a PhD student from September 2010 to September 2014.

Irene also gained valuable experience as a Visiting PhD Student at DKFZ-NCT - Section Molecular and Gene Therapy from March 2014 to May 2014, and at NCT - Section Molecular and Gene Therapy from July 2013 to October 2013.

Their career began as an Undergraduate Student at Instituto de Investigaciones Sanitarias (IDIS) - Reumatología Experimental, where they were involved in protein methods research from September 2009 to June 2010. Irene also worked as an Undergraduate Student at Universidade de Santiago de Compostela - UETeM (Facultade de Medicina) from October 2006 to June 2009.

Irene Gil Farina obtained a Bachelor of Science (BS) in Molecular Biology from the University of Santiago de Compostela from 2005 to 2010. Following this, they pursued a Master of Biomedical Research at the University of Navarra from 2010 to 2011. Irene then continued their education at the Universidad de Navarra, where they completed their Doctor of Philosophy (Ph.D.) in the Department of Hepatology and Gene Therapy from 2010 to 2014.